Sun Daoyuan, Yang Wenlan, Wang Zhenwei, Gao Beilan
Department of Toxicology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China (mainland).
Med Sci Monit. 2021 Feb 3;27:e928413. doi: 10.12659/MSM.928413.
BACKGROUND To explore the efficacy of beraprost sodium combined with sildenafil and its effects on the vascular endothelial function and inflammation in left heart failure patients complicated with pulmonary arterial hypertension. MATERIAL AND METHODS A total of 80 patients with left heart failure complicated with pulmonary arterial hypertension was enrolled as the subjects of this study and assigned into an observation group (n=40) and a control group (n=40) using a random number table. The changes in pulmonary arterial hypertension-associated indicators at 3 months after treatment and the alterations in the levels of cardiac function-associated biochemical indicator brain natriuretic peptide (BNP), inflammatory factor tumor necrosis factor alpha (TNF-alpha), and mean pulmonary arterial pressure during treatment were compared between the 2 groups. RESULTS At 3 months after treatment, the pulmonary arterial hypertension-associated indicators human urotensin II and calcitonin gene-related peptide in the observation group were lower and higher, respectively, than those in control group. Moreover, the observation group had significantly lower BNP and TNF-alpha levels and mean pulmonary arterial pressure than the control group. After intervention, the echocardiographic parameters left ventricular ejection fraction (LVEF), cardiac output (CO), and stroke volume (SV) in both groups were significantly higher than those before intervention, and the observation group had significantly higher LVEF, SV, and CO than the control group after intervention. CONCLUSIONS Beraprost sodium combined with sildenafil for left heart failure complicated with pulmonary arterial hypertension can effectively improve pulmonary arterial hypertension, alleviate left heart failure, and reduce inflammatory responses, thereby achieving better clinical efficacy in patients.
背景 探讨贝前列素钠联合西地那非治疗左心衰竭合并肺动脉高压患者的疗效及其对血管内皮功能和炎症的影响。
材料与方法 选取80例左心衰竭合并肺动脉高压患者作为本研究对象，采用随机数字表法分为观察组（n = 40）和对照组（n = 40）。比较两组治疗3个月后肺动脉高压相关指标的变化以及治疗期间心功能相关生化指标脑钠肽（BNP）、炎症因子肿瘤坏死因子α（TNF-α）水平及平均肺动脉压的改变。
结果 治疗3个月后，观察组肺动脉高压相关指标人尿钠肽原和降钙素基因相关肽分别低于和高于对照组。此外，观察组BNP、TNF-α水平及平均肺动脉压均显著低于对照组。干预后，两组超声心动图参数左心室射血分数（LVEF）、心输出量（CO）和每搏输出量（SV）均显著高于干预前，且干预后观察组LVEF、SV和CO均显著高于对照组。
结论 贝前列素钠联合西地那非治疗左心衰竭合并肺动脉高压可有效改善肺动脉高压，减轻左心衰竭，降低炎症反应，从而使患者获得更好的临床疗效。
